AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01541852
Drug: Losmapimod
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of Losmapimod 7.5mg twice daily
Trial: NCT04916899
Drug: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
Trial: NCT01152541
Drug: Riboflavin/Dextran
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
Trial: NCT01152541
Drug: Hypotonic Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
Trial: NCT02806362
Drug: Ombitasvir/paritaprevir/ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT02393742
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01852461
Drug: Beractant
RxNorm normalized name: Beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
Trial: NCT01852461
Drug: Poractant alfa
RxNorm normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
Trial: NCT02132832
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Trial: NCT00919191
Drug: Adapalene and Benzoyl peroxide
RxNorm normalized name: Adapalene and Benzoyl Peroxide Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene .1% and Benzoyl peroxide 2.5%
Trial: NCT00541853
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan upto 8mg
Trial: NCT00541853
Drug: Candesartan and Cilnidipine
RxNorm normalized name: candesartan and diuretics
DrugBank: Cilnidipine (DB09232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
Trial: NCT00385450
Drug: Nelfinavir/placebo
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1250mg/twice each day/four days.
Trial: NCT00541853
Drug: Candesartan plus non-CCB agents
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
Trial: NCT03822975
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.
Trial: NCT03822975
Drug: unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
Trial: NCT03812029
Drug: Vonafexor
RxNorm normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01132820
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00677534
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 Units PO Twice weekly for 8 weeks
Trial: NCT00296257
Drug: SMP-114
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03733353
Drug: EDP1815
RxNorm normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 is an orally administered monoclonal microbial
Trial: NCT01821404
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules including 80 mg of atorvastatin
Trial: NCT02228902
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
Trial: NCT02228902
Drug: Ferrous gluconate
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One group receives ferrous fumarate and one group receives ferrous fumarate.
Trial: NCT04142060
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
Trial: NCT00332462
Drug: Cyclosporine (Sandimmun® i.v.)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Trial: NCT00332462
Drug: Cyclosporine (Sandimmun® Optoral)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Trial: NCT00039663
Drug: Gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00039663
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01527747
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg daily
Trial: NCT00863681
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
Trial: NCT02764268
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01148342
Drug: MDMA
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01148342
Drug: (+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 1.0 \&amp; 1.6 mg/kg
Trial: NCT01236638
Drug: Momelotinib
RxNorm normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
Trial: NCT00338962
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paroxetine (40mg/day)
Trial: NCT00338962
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg per day
Trial: NCT00175643
Drug: imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02207855
Drug: Chloroprocaine
RxNorm normalized name: Chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01359787
Drug: Mapracorat
RxNorm normalized name: Mapracorat
DrugBank: Mapracorat (DB12041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical application
Trial: NCT01359787
Drug: Vehicle without active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical application
Trial: NCT01832415
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Observation of bevacizumab administration in first line ovarian cancer treatment
Trial: NCT03815812
Drug: IBI306
RxNorm normalized name: Immunoglobulin igg2, anti-(human proprotein convertase subtilisin/kexin type 9) (human monoclonal ibi306 .gamma.2-chain), disulfide with human monoclonal ibi306 .kappa.-chain, dimer
DrugBank: Tafolecimab (DB16336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
Trial: NCT01860326
Drug: Alisporivir
RxNorm normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules supplied as open labeled bulk medication in 10-unit blister packages
Trial: NCT02537223
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04432402
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
Trial: NCT02406261
Drug: Lanabecestat
RxNorm normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
Trial: NCT03225326
Drug: Computer controlled 4% articaine delivery by Anaeject
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
Trial: NCT03225326
Drug: Conventional 4% articaine delivery by carpule syringe
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
Trial: NCT02406261
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
Trial: NCT02406261
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
Trial: NCT02406261
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg donepezil will be administered orally as 1 × 5-mg tablet
Trial: NCT01165840
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PO x 1 dose
Trial: NCT00199030
Drug: Alemtuzumab (MabCampath)
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199030
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01280240
Drug: Monofer(R)
RxNorm normalized name: Monoferric
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection given over app. 2 minutes only once
Trial: NCT02797080
Drug: interferon γ-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
Trial: NCT02650895
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT00230321
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
Trial: NCT00001197
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00832338
Drug: Docetaxel with Cytoxan
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
Trial: NCT02097303
Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
Trial: NCT01777165
Drug: ABT-719
RxNorm normalized name: ABT-925
DrugBank: ABT-751 (DB12254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
Trial: NCT00832338
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
Trial: NCT05506865
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
Trial: NCT05506865
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
Trial: NCT02398669
Drug: Lorcaserin hydrochloride
RxNorm normalized name: Lorcaserin Hydrochloride
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
Trial: NCT01948362
Drug: Alpha cyclodextrin
RxNorm normalized name: alpha cyclodextrin
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT00152490
Drug: Certolizumab Pegol (CDP870)
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02222896
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% CHG solution on cloth
Trial: NCT02222896
Drug: DynaHex-2
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% CHG solution
Trial: NCT00601718
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00601718
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00601718
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00601718
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02744248
Drug: IOP Injection
RxNorm normalized name: AVOBENZONE 1.25 g in 50 mL / HOMOSALATE 4.5 g in 50 mL / OCTISALATE 2.25 g in 50 mL / OCTOCRYLENE 4.5 g in 50 mL TOPICAL CREAM [IOPE UV DEFENSE SUN PROTECTOR]
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IOP Injection 20 mg Fe/ml, intravenous injection
Trial: NCT02597712
Drug: YF476
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gastrin receptor antagonist
Trial: NCT03335436
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
Trial: NCT00053872
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053872
Drug: lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053872
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03490838
Drug: 177Lu-PSMA-R2
RxNorm normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radio-ligand therapy
Trial: NCT01441635
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix tablets
Trial: NCT01441635
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
Trial: NCT02799641
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg Diazepam
Trial: NCT02799641
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 ml of 2% lidocaine
Trial: NCT02078128
Drug: oral sugar powder
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Trial: NCT04760262
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Trial: NCT04760262
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Trial: NCT03514277
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
Trial: NCT03514277
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL bupivacaine 0.5% w/v solution
Trial: NCT00033618
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02489240
Drug: vitamin D3 tablets
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU vitamin D3 tablets were taken daily for 6 days
Trial: NCT00414167
Drug: bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg per day for 8 weeks
Trial: NCT02713477
Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous